Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

GRAL vs DGX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

DGX Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 7–3 Matrix Metrics)

DGX Overall Winner 6-Pillar Tally: GRAL 1 – 5 DGX Matrix Metrics: GRAL 3 – 7 DGX

As of Nov 16, 2026, Quest Diagnostics Inc. (DGX) is the stronger overall head-to-head candidate over GRAIL, Inc. (GRAL) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). GRAL carries a Unified Composite Score of 54.5/100 (HOLD) at $105.60 (1.1x Forward P/E, -332.0% operating margin), whereas DGX carries 41.1/100 (SELL) at $262.21 (21.9x Forward P/E, 14.9% operating margin).

  • Composite vs. Pillar Nuance: While GRAL currently prints a higher short-term Unified Composite Score (54.5/100 HOLD vs. DGX 41.1/100 SELL), DGX captures the overall institutional head-to-head verdict (7–3 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (14.9% vs. -332.0% operating margin) and revenue trajectory (+10.0% vs. +3.7% YoY).
  • Technical & Structure Timing Caution: GRAL is currently in a Breakdown options structure phase (RSI 37.7); meanwhile DGX trades in a Markup technical trend (CONSOLIDATION options phase, RSI 71.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About GRAL vs DGX
GRAL NASDAQ
GRAIL, Inc. Common Stock
Services-Medical Laboratories
$105.60
-8.88% 1D
Market Cap $5.2B
TTM Revenue $167M
Forward P/E 1.1x
Beta / 30D Vol 3.09β · 99% Vol
Unified Composite Score
54.5 / 100 HOLD
Tech 35.0 Fund 49.0 Flow 57.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 38
RSI-14: 37.7 · SMA20: $132.32 · SMA50: $121.37
DGX NYSE Head-to-Head Winner
Quest Diagnostics Inc.
Services-Medical Laboratories
$262.21
+1.01% 1D
Market Cap $28.6B
TTM Revenue $11.8B
Forward P/E 21.9x
Beta / 30D Vol -0.06β · 19% Vol
Unified Composite Score
41.1 / 100 SELL
Tech 21.0 Fund 37.0 Flow 55.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (1.9% over 20 days), RSI 72
RSI-14: 71.6 · SMA20: $250.96 · SMA50: $241.80

6-Pillar Scorecard Institutional Category Breakdown (GRAL 1 – 5 DGX)

Columns: Metric · GRAL · DGX
1. Valuation Multiples GRAL
Forward P/E 1.1x 21.9x
Trailing P/E 1.1x 25.9x
PEG Ratio N/M 1.68x
EV / Revenue 31.6x 2.9x
2. Growth & Scale DGX
Revenue Growth (YoY) +3.7% +10.0%
Earnings Growth (YoY) +0.0% +28.7%
TTM Revenue (USD) $167M $11.8B
Market Cap $5.2B $28.6B
3. Profitability & Quality DGX
Gross Margin 46.7% 33.2%
Operating Margin -332.0% 14.9%
Net Profit Margin -243.8% 9.5%
Return on Equity (ROE) -17.3% 15.3%
4. Balance Sheet & Cash Flow DGX
Cash Generation (TTM) -$312M $1.38B
Cash Flow Margin N/A 11.6%
Net Cash / Leverage $57M Net Debt (0.03x D/E) $5.49B Net Debt (0.82x D/E)
Dividend Yield None (0.00%) 1.30%
5. Options & Positioning DGX
Options Structure Phase BREAKDOWN CONSOLIDATION
Current IV / %ile 93.0% (53rd %ile) 29.3% (16th %ile)
Put/Call OI Skew 0.81x (Call-Skewed) 0.29x (Call-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Neutral ACCUMULATION · Markup
6. R&D & Supply-Chain Moat DGX
OpEx & R&D Intensity N/A 18.3% of Rev ($2.17B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Diagnostics & Research Operator Diagnostics & Research Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: GRAL (3) vs DGX (7)
Institutional Metric GRAL DGX Criterion Row Edge
Market Capitalization
Scale
$5.2B $28.6B Larger Scale DGX
Trailing P/E Ratio
Valuation
1.1x 25.9x Lower Multiple GRAL
Forward P/E Ratio
Valuation
1.1x 21.9x Lower Multiple GRAL
Revenue Growth (YoY)
Growth
+3.7% +10.0% Higher Growth DGX
Operating Margin (TTM)
Profitability
-332.0% 14.9% Higher Margin DGX
Net Profit Margin
Profitability
-243.8% 9.5% Higher Margin DGX
Return on Equity (ROE)
Capital Efficiency
-17.3% 15.3% Higher ROE DGX
52-Week Range Position
Momentum
51% ($42–$166) 99% ($171–$263) Stronger Trend DGX
Beta / 30D Volatility
Risk Regime
3.09β · 99% Vol -0.06β · 19% Vol Lower Realized Risk DGX
Unified Institutional Score
Composite Signal
54.5 / 100 (HOLD) 41.1 / 100 (SELL) Higher Composite GRAL
Trailing 12M Revenue (USD)
Operating Scale
$167M $11.8B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
46.7% 33.2% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 31.6x EV/Rev 1.68x PEG · 2.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$312M ($57M Net Debt (0.03x D/E)) $1.38B ($5.49B Net Debt (0.82x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon DGX +21.94 pp
GRAL: -10.36% · DGX: +11.58%
3M Horizon GRAL +39.63 pp
GRAL: +50.96% · DGX: +11.33%
6M Horizon GRAL +36.52 pp
GRAL: +77.03% · DGX: +40.51%
1Y Horizon DGX +12.87 pp
GRAL: +26.92% · DGX: +39.79%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period GRAL Revenue DGX Revenue GRAL Op. Margin DGX Op. Margin Margin Leader
FY2018 N/A $7.53B N/A 14.6% DGX
FY2019 N/A $7.73B N/A 15.9% DGX
FY2020 N/A $9.44B N/A 20.9% DGX
FY2021 N/A $10.8B N/A 22.1% DGX
FY2022 N/A $9.88B N/A 14.4% DGX
FY2023 $90M $9.25B -1627.6% 13.6% DGX
FY2024 $130M $9.87B -1743.0% 13.6% DGX
FY2025 $150M $11.0B -382.0% 14.1% DGX

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
GRAL BREAKDOWN
12d in phase · OBV DISTRIBUTION
Current IV 93.0%
IV Percentile 53rd %ile
Put/Call OI Skew 0.81x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact GRAL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
DGX CONSOLIDATION
71d in phase · OBV ACCUMULATION
Current IV 29.3%
IV Percentile 16th %ile
Put/Call OI Skew 0.29x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact DGX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
GRAL Moat Profile Cyclical / Execution-Driven Positioning
Diagnostics & Research Operator
Competes within the Diagnostics & Research value chain with $5.2B market capitalization and -332.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
DGX Moat Profile Cyclical / Execution-Driven Positioning
Diagnostics & Research Operator
Competes within the Diagnostics & Research value chain with $28.6B market capitalization and 14.9% operating margin.
OpEx & R&D Reinvestment 18.3% of Rev ($2.17B)
90D Engineering Disclosures 0 Published

Investor FAQ GRAL vs DGX Key Questions & Quantitative Answers

As of Nov 16, 2026, Quest Diagnostics Inc. (DGX) is the stronger overall head-to-head candidate over GRAIL, Inc. (GRAL) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). GRAL carries a Unified Composite Score of 54.5/100 (HOLD) at $105.60 (1.1x Forward P/E, -332.0% operating margin), whereas DGX carries 41.1/100 (SELL) at $262.21 (21.9x Forward P/E, 14.9% operating margin). Composite vs. Pillar Nuance: While GRAL currently prints a higher short-term Unified Composite Score (54.5/100 HOLD vs. DGX 41.1/100 SELL), DGX captures the overall institutional head-to-head verdict (7–3 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (14.9% vs. -332.0% operating margin) and revenue trajectory (+10.0% vs. +3.7% YoY). Technical & Structure Timing Caution: GRAL is currently in a Breakdown options structure phase (RSI 37.7); meanwhile DGX trades in a Markup technical trend (CONSOLIDATION options phase, RSI 71.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

DGX leads the Growth & Scale pillar: GRAL posts +3.7% YoY revenue growth and +0.0% YoY earnings growth on $167M TTM revenue (46.7% gross margin, -332.0% operating margin), compared with DGX at +10.0% YoY revenue growth and +28.7% YoY earnings growth on $11.8B TTM revenue (33.2% gross margin, 14.9% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), GRAL cumulative revenue shifted +66.7% while DGX shifted +46.6%. In operating R&D and SG&A reinvestment, GRAL deploys N/A (0 90-day corporate R&D disclosures) versus 18.3% of Rev ($2.17B) (0 disclosures) for DGX.

GRAL screens cheaper on headline valuation multiples. GRAL trades at 1.1x Forward P/E, 1.1x Trailing P/E, N/M PEG, and 31.6x EV/Revenue (unreported FCF margin), whereas DGX trades at 21.9x Forward P/E, 25.9x Trailing P/E, 1.68x PEG, and 2.9x EV/Revenue (11.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against GRAL (-17.3% ROE) versus DGX (15.3% ROE) capital efficiency.

In options market volatility and institutional positioning, GRAL carries 93.0% implied volatility (53rd %ile, Balanced (25th–60th %ile)), a 0.81x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (3.09β · 99% Vol realized risk). By comparison, DGX carries 29.3% implied volatility (16th %ile, Compressed (<25th %ile)), a 0.29x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (-0.06β · 19% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.